Special Issue "Multicomponent Reaction-Based Synthesis of Bioactive Molecules"
Deadline for manuscript submissions: closed (30 June 2017).
Interests: multitarget anti-Alzheimer agents; hybrid compounds; cholinesterase inhibitors; amyloid anti-aggregating compounds; BACE-1 inhibitors; antiprotozoan compounds
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Emerging Drug Discovery Approaches against Infectious Diseases
Special Issue in Molecules: Present and Future of Medicinal Chemistry Research: A Young Researchers’ Perspective
Special Issue in Molecules: Molecules against Alzheimer II
Special Issue in Molecules: Facing Novel Challenges in Drug Discovery
Topical Collection in Molecules: Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
Special Issue in Molecules: Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 2020
Special Issue in Molecules: Feature Papers to Celebrate Molecules Reaches 20,000 Articles Milestone
Special Issue in Molecules: 25th Anniversary of Molecules—Recent Advances in Medicinal Chemistry
Special Issue in Molecules: Molecules Medicinal Chemistry Reviews 2021
Interests: multicomponent reactions; heterocyclic chemistry; scaffolds for medicinal chemistry; functional fluorophores; chemical biology
Interests: multicomponent reactions; medicinal chemistry; diversity oriented synthesis; neurodegeneration
Multicomponent reactions (MCRs) involve the one-pot combination of three or more reactants to afford single products that feature structural elements of all the starting materials, thereby displaying a high degree of synthetic efficiency and atom economy. Because of their modular features, MCRs generate complex products, ideally in one step, amenable to a broad range of substitution patterns. This strategy represents a powerful tool for combinatorial and diversity-oriented synthesis, and hence, a compelling approach for new hit discovery and hit-to-lead optimization campaigns. As a consequence, MCRs are having a tremendous impact in drug discovery both in the pharmaceutical industry and in academia.
In this Special Issue, we intend to collect original research articles and short communications about medicinal chemistry projects where MCRs have played an important role in the synthesis of the target biologically active compounds or their advanced precursors. Review articles that address the role of known MCRs and the design of novel MCRs for drug discovery will be also welcome.
Prof. Dr. Diego Muñoz-Torrero
Prof. Dr. Rodolfo Lavilla
Prof. Dr. Christopher Hulme
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multicomponent reactions
- drug discovery
- hit-to-lead optimization
- diversity-oriented synthesis
- structural complexity
- exploratory power
- iterative efficiency